The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide
Abstract Introduction Herpes zoster (HZ, Shingles) is a vaccine-preventable viral disease impacting patients’ quality of life owing to pain and rash. An estimated 15 million HZ cases occur annually in individuals aged ≥ 50 years worldwide. Recombinant zoster vaccine (RZV) is effective in protecting...
Saved in:
| Main Authors: | Nikolaos Giannelos, Desmond Curran, Sean Matthews, Justin Carrico, Anthony L. Cunningham |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-05-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01161-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative NetworkResearch in context
by: Ying-Li Lin, et al.
Published: (2025-07-01) -
Current status of immunisation for herpes zoster
by: Anthony Lawrence Cunningham, et al.
Published: (2025-12-01) -
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States
by: Ana Florea, et al.
Published: (2024-12-01) -
Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial
by: Diana Alexandra Echeverria Proano, et al.
Published: (2024-12-01) -
The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain
by: Andrea García, et al.
Published: (2024-12-01)